New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36758550.
- Also identified by DOI 10.1097/RLU.0000000000004589.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177 Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) received 1 cycle of 161 Tb-PSMA RLT. This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence of the therapeutic potential of 161 Tb-PSMA RLT in metastatic castration-resistant prostate cancer, even in patients progressing after extensive 177 Lu-based RLT. 161 Tb-labeled PSMA ligands may thus offer a promising alternative to standard PSMA RLT.
Medical subject headings
- Radioisotopes
- Prostatic Neoplasms, Castration-Resistant